



Robert Greene Sterne RODERT Greene Steme Edward J. Kessler Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Donald J. Featherstone

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston

Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich* George S. Bardmesser Daniel A. Klein* Jason D. Fisenbern Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis John J. Figueroa Ann E. Summerfield Tiera S. Coston Jessica L. Parezo

Timothy A. Doyle* Gaby L. Longsworth* Nicole D. Dretar* Ted J. Ebersole Jyoti C. Iyer*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford

Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia • Practice Limited to Federal Agencies

June 22, 2004

WRITER'S DIRECT NUMBER: (202) 772-8762 INTERNET ADDRESS: NLEITH@SKGF.COM

Art Unit 1642

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/734,625; Filed: December 15, 2003

Lipoxygenase Inhibitors as Hypolipidemic and Anti-Hypertensive

Agents

Inventors:

ALLAN et al.

Our Ref:

1633.0400002/SRL/NJL

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement;
- 2. 1 page of Form PTO-1449 citing 2 documents;
- 3. Copy of 1 of the cited documents; and
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents June 22, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Nancy J. Leith

Agent for Applicants Registration No. 45,309

SRL/NJL:cpn Enclosures

278995_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No. 2541

Allan et al.

Art Unit:

1642

Appl. No. 10/734,625

Examiner:

To be assigned

Filed: December 15, 2003

Atty. Docket: 1633.0400002/SRL/NJL

For:

Lipoxygenase Inhibitors as Hypolipidemic and Anti-

Hypertensive Agents

First Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed March 15, 2004, in connection with the above-captioned application.

A copy of document AF3 is not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003." A copy of each other document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Nancy J. Leith

Agent for Applicants

Nancy J. Lein

Registration No. 45,309

une 22,2005 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 278791 1.DOC

| حب ب ـــــــــــــــــــــــــــــــــــ | | | OIP | E | | | | | |
|---|-----------------|---------|-------------------------------------|--------------------|--|------------------|--|-----------------|--|
| | F | ORM F | JUN 2 2 | 2004 | ATTY. DOCKET NO. 1633.0400002/SRL/NJL FIRST NAMED INVENTOR | | Page 1 of 1 APPLICATION NO. 10/734,625 | | |
| FIRST SUPPLEMENTAL TRADEMENT | | | | | Allan <i>et al.</i> FILING DATE December 15, 2003 | ART | ART UNIT 1642 | | |
| | | | | US PATE | NT DOCUMENTS | | | | |
| EXAMINER INITIAL | | DC | CUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE | |
| INTIAL | AA | | OOMENT NOMBER | DAIL | TVVVI | 02/100 | 000 00.00 | TIENCO DATE | |
| • | AB | | | | | | | | |
| | AC | | | | | | | | |
| <u> </u> | AD | | | | | - | + | - | |
| | AE | | | | | | | | |
| • | AF3 | 4,4 | 486,593 | 12/04/1984 | Lin | | | 01/19/1983 | |
| | AG | | | | | | | | |
| | AH | | | | | | | | |
| <u> </u> | Al | | | | | | | | |
| | AJ | | | | | | | | |
| | AK | | | | | | | | |
| EXAMINER | | | F | OREIGN PA | TENT DOCUMENTS | ı | T | T | |
| INITIAL | | DC | CUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION Yes | |
| | AL | | · | | | | | No Yes | |
| | AM | | | | | | | No Yes | |
| | AN | | | | | | | No | |
| | AO | | | | | | | Yes No | |
| | AP | | ···· | | | | | Yes No | |
| | | | OTHER (Includ | ding Author, | Title, Date, Pertinent F | Pages, etc.) | | | |
| | AR | 14 | International Se 18, 2004, Alexa | | or PCT Patent Application | on No. PCT/U | 303/40254, r | mailed May | |
| | AS | | | | | | | | |
| | AT | | | | | | | | |
| EXAMINER | | 1 | | | | DATE CONSIDERED | | | |
| EXAMINER: I | nitial if refer | ence co | onsidered, whether or | not citation is in | conformance with MPEP 609. | Draw line throug | h citation if not | in conformance | |
| and not consid | erea. Inclu | ue copy | of this form with next | communication | to Applicant. | | | | |